Babette Bais1, Nina M Molenaar2, Hilmar H Bijma3, Witte J G Hoogendijk4, Cornelis L Mulder5, Annemarie I Luik6, Mijke P Lambregtse-van den Berg7, Astrid M Kamperman8. 1. Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. Electronic address: b.bais@erasmusmc.nl. 2. Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands; Icahn School of Medicine at Mount Sinaï, New York, United States. 3. Department of Obstetrics and Gynaecology, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. 4. Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. 5. Epidemiological and Social Psychiatric Research Institute, Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands; Parnassia Bavo Group, Rotterdam, the Netherlands. 6. Department of Epidemiology, Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. 7. Department of Child and Adolescent Psychiatry/Psychology, Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands. 8. Epidemiological and Social Psychiatric Research Institute, Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
Abstract
BACKGROUND: Maternal use of benzodiazepines during pregnancy is common and has increased over the last decades. In this systematic review and meta-analysis, we studied the literature to estimate the worldwide use of benzodiazepines before, during and after pregnancy, which could help to estimate benzodiazepine exposure and to prioritize and guide future investigations. METHODS: We systematically searched Embase, Medline Ovid, Web of Science and Cochrane Central up until July 2019 for studies reporting on benzodiazepine use before (12 months), during and after pregnancy (12 months). Random effects meta-analysis was conducted to calculate pooled prevalence estimates, as well as stratified according to substantive variables. RESULTS: We identified 32 studies reporting on 28 countries, together reporting on 7,343,571 pregnancies. The worldwide prevalence of benzodiazepine use/prescriptions during pregnancy was 1.9% (95%CI 1.6%-2.2%; I2 97.48%). Highest prevalence was found in the third trimester (3.1%; 95%CI 1.8%-4.5%; I2 99.83%). Lorazepam was the most frequently used/prescribed benzodiazepine (1.5%; 95%CI 0.5%-2.5%; I2 99.87%). Highest prevalence was found in Eastern Europe (14.0%; 95%CI 12.1%-15.9%; I2 0.00%). LIMITATIONS: All analyses revealed considerable heterogeneity. CONCLUSIONS: Our meta-analysis confirmed that benzodiazepine use before, during and after pregnancy is prevalent. The relatively common use of benzodiazepines with possible risks for both mother and (unborn) child is worrying and calls for prescription guidelines for women, starting in the preconception period. Given the substantial proportion of children exposed to benzodiazepines in utero, future research should continue to study the short- and long-term safety of maternal benzodiazepine use during pregnancy and to explore non-pharmacological alternative treatments.
BACKGROUND: Maternal use of benzodiazepines during pregnancy is common and has increased over the last decades. In this systematic review and meta-analysis, we studied the literature to estimate the worldwide use of benzodiazepines before, during and after pregnancy, which could help to estimate benzodiazepine exposure and to prioritize and guide future investigations. METHODS: We systematically searched Embase, Medline Ovid, Web of Science and Cochrane Central up until July 2019 for studies reporting on benzodiazepine use before (12 months), during and after pregnancy (12 months). Random effects meta-analysis was conducted to calculate pooled prevalence estimates, as well as stratified according to substantive variables. RESULTS: We identified 32 studies reporting on 28 countries, together reporting on 7,343,571 pregnancies. The worldwide prevalence of benzodiazepine use/prescriptions during pregnancy was 1.9% (95%CI 1.6%-2.2%; I2 97.48%). Highest prevalence was found in the third trimester (3.1%; 95%CI 1.8%-4.5%; I2 99.83%). Lorazepam was the most frequently used/prescribed benzodiazepine (1.5%; 95%CI 0.5%-2.5%; I2 99.87%). Highest prevalence was found in Eastern Europe (14.0%; 95%CI 12.1%-15.9%; I2 0.00%). LIMITATIONS: All analyses revealed considerable heterogeneity. CONCLUSIONS: Our meta-analysis confirmed that benzodiazepine use before, during and after pregnancy is prevalent. The relatively common use of benzodiazepines with possible risks for both mother and (unborn) child is worrying and calls for prescription guidelines for women, starting in the preconception period. Given the substantial proportion of children exposed to benzodiazepines in utero, future research should continue to study the short- and long-term safety of maternal benzodiazepine use during pregnancy and to explore non-pharmacological alternative treatments.
Authors: Carlos Aparecido da Silva Junior; Luís Gustavo A Patrone; Vivian Biancardi; Heloísa H Vilela-Costa; Danuzia A Marques; Caroline Cristina-Silva; Kaoma Stephani da Costa Silva; Kênia C Bícego; Raphael E Szawka; Luciane H Gargaglioni Journal: Pflugers Arch Date: 2022-07-25 Impact factor: 4.458
Authors: Satu-Maarit Björkstedt; Hannu Kautiainen; Ulla Tuomi; Mika Gissler; Pirjo Pennanen; Johan G Eriksson; Merja K Laine Journal: Sci Rep Date: 2021-02-24 Impact factor: 4.379
Authors: Sarah Kittel-Schneider; Ethel Felice; Rachel Buhagiar; Mijke Lambregtse-van den Berg; Claire A Wilson; Visnja Banjac Baljak; Katarina Savic Vujovic; Branislava Medic; Ana Opankovic; Ana Fonseca; Angela Lupattelli Journal: Int J Environ Res Public Health Date: 2022-02-10 Impact factor: 3.390
Authors: Laura Palagini; Alessandra Bramante; Chiara Baglioni; Nicole Tang; Luigi Grassi; Ellemarije Altena; Anna F Johann; Pierre Alexis Geoffroy; Giovanni Biggio; Claudio Mencacci; Verinder Sharma; Dieter Riemann Journal: Arch Womens Ment Health Date: 2022-04-13 Impact factor: 4.405
Authors: Ludvig D Bjørndal; Fatima Tauqeer; Kristin S Heiervang; Hanne K Clausen; Kristine Heitmann; Angela Lupattelli Journal: BMJ Open Date: 2022-09-30 Impact factor: 3.006